These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31090914)

  • 41. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.
    Sapp JL; Parkash R; Wells GA; Yetisir E; Gardner MJ; Healey JS; Thibault B; Sterns LD; Birnie D; Nery PB; Sivakumaran S; Essebag V; Dorian P; Tang AS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28292754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
    Singh S; Murawski MM
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):175-80. PubMed ID: 17875944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.
    Friedman PA; McClelland RL; Bamlet WR; Acosta H; Kessler D; Munger TM; Kavesh NG; Wood M; Daoud E; Massumi A; Schuger C; Shorofsky S; Wilkoff B; Glikson M
    Circulation; 2006 Jun; 113(25):2871-9. PubMed ID: 16769912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Importance of monitoring zones in the detection of arrhythmias in patients with implantable cardioverter-defibrillators under remote monitoring.
    Aguiar Rosa S; Silva Cunha P; Lousinha A; Valente B; Delgado AS; Pimenta R; Brás M; Coutinho Cruz M; Portugal G; Viveiros Monteiro A; Oliveira M; Cruz Ferreira R
    Rev Port Cardiol (Engl Ed); 2019 Jan; 38(1):11-16. PubMed ID: 30686652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitachycardia pacing therapy for the successful treatment of lead fracture.
    Bhimani AA; Deeprasertkul P; Nannapaneni N; Carayannopoulos GN
    J Cardiovasc Electrophysiol; 2015 Feb; 26(2):228-9. PubMed ID: 25354719
    [No Abstract]   [Full Text] [Related]  

  • 49. Is defibrillation testing necessary?
    Russo AM; Chung MK
    Cardiol Clin; 2014 May; 32(2):211-24. PubMed ID: 24793798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erratum to '2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing' [Journal of Arrhythmia 32/1 (2016) 1-28].
    Wilkoff BL; Fauchier L; Stiles MK; Morillo CA; Al-Khatib SM; Almendral J; Aguinaga L; Berger RD; Cuesta A; Daubert JP; Dubner S; Ellenbogen KA; Mark Estes NA; Fenelon G; Garcia FC; Gasparini M; Haines DE; Healey JS; Hurtwitz JL; Keegan R; Kolb C; Kuck KH; Marinskis G; Martinelli M; McGuire M; Molina LG; Okumura K; Proclemer A; Russo AM; Singh JP; Swerdlow CD; Teo WS; Uribe W; Viskin S; Wang CC; Zhang S
    J Arrhythm; 2016 Oct; 32(5):441-442. PubMed ID: 27761170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trends in implantable cardioverter-defibrillator programming practices and its impact on therapies: Insights from a North American Remote Monitoring Registry 2007-2018.
    Bennett MT; Brown ML; Koehler J; Lexcen DR; Cheng A; Cheung JW
    Heart Rhythm; 2022 Feb; 19(2):219-225. PubMed ID: 34656774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Wearable cardioverter-defibrillator as a bridge to implantable cardioverter-defibrillator treatment.
    Technol Eval Cent Assess Program Exec Summ; 2010 Nov; 25(2):1-5. PubMed ID: 21638938
    [No Abstract]   [Full Text] [Related]  

  • 53. Approach to reduction of ventricular arrhythmias and implantable cardioverter-defibrillator therapies in patients with heart failure.
    Sengupta J; Abdelhadi R
    Curr Opin Cardiol; 2013 May; 28(3):337-43. PubMed ID: 23549236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Competitive athletes with implantable cardioverter-defibrillators-How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry.
    Olshansky B; Atteya G; Cannom D; Heidbuchel H; Saarel EV; Anfinsen OG; Cheng A; Gold MR; Müssigbrodt A; Patton KK; Saxon LA; Wilkoff BL; Willems R; Dziura J; Li F; Brandt C; Simone L; Wilhelm M; Lampert R
    Heart Rhythm; 2019 Apr; 16(4):581-587. PubMed ID: 30389442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome.
    Goldenberg I; Huang DT; Nielsen JC
    Eur Heart J; 2020 Jun; 41(21):2003-2011. PubMed ID: 31713598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.
    Clementy N; Challal F; Marijon E; Boveda S; Defaye P; Leclercq C; Deharo JC; Sadoul N; Klug D; Piot O; Gras D; Bordachar P; Algalarrondo V; Fauchier L; Babuty D;
    Heart Rhythm; 2017 Feb; 14(2):211-217. PubMed ID: 27989789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tachycardia detection in modern implantable cardioverter-defibrillators.
    Brüggemann T; Dahlke D; Chebbo A; Neumann I
    Herzschrittmacherther Elektrophysiol; 2016 Sep; 27(3):171-85. PubMed ID: 27576695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential proarrhythmic effects of implantable cardioverter-defibrillators.
    Duru F; Candinas R
    Clin Cardiol; 1999 Feb; 22(2):139-46. PubMed ID: 10068856
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Implantable cardioverter-defibrillators in the prevention of sudden cardiac death].
    Kozák M; Krivan L; Semrád B
    Vnitr Lek; 2001 Jun; 47(6):361-70. PubMed ID: 11494881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.